CryoLife (Cry) (WKN: 900006)

Kurzporträt

Provides cryopreserved human tissue for vascular transplant applications

CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries.

It operates through Medical Devices and Preservation Services segments.

The Medical Devices segment includes external revenues from product sales of BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, HeRO Graft, and ProCol.

The Preservation Services segment offers external services revenues from the preservation of cardiac and vascular tissues.

The company was founded by Steven G. Anderson on January 19, 1984 and is headquartered in Kennesaw, GA.

de.4-traders.com/CRYOLIFE-INC-12185/unternehmen/

phx.corporate-ir.net/phoenix.zhtml?c=80253&p=irol-IRHome

seekingalpha.com/symbol/CRY?s=cry

financials.morningstar.com/...ment/is.html?t=CRY&ops=clear

investors.cryolife.com/news-releases/...reement-acquire-jotec/

seekingalpha.com/article/...-results-earnings-call-transcript

seekingalpha.com/article/...-results-earnings-call-transcript

www.jotec.com/de/produkte.html

www.marketscreener.com/CRYOLIFE-INC-12185/...apshot-28007615/

seekingalpha.com/article/...-results-earnings-call-transcript

investors.cryolife.com/static-files/...-4239-b218-cbc98f8129cf

www.marketscreener.com/CRYOLIFE-INC-12185/...apshot-28512147/


04/30/2019 | 05:20pm EDT
KENNESAW, Ga. (AP) _ CryoLife Inc. (CRY) on Tuesday reported a loss of $297,000 in its first quarter.
On a per-share basis, the Kennesaw, Georgia-based company said it had a loss of 1 cent. Earnings, adjusted for one-time gains and costs, were 4 cents per share.
The biological medical device maker posted revenue of $67.5 million in the period.
CryoLife expects full-year earnings in the range of 28 cents to 32 cents per share, with revenue in the range of $280 million to $284 million.
CryoLife shares have increased 8% since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $30.66, a climb of 37% in the last 12 months.
This story was generated by Automated Insights (automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CRY at www.zacks.com/ap/CRY
Automated Insights, source Associated Press News

seekingalpha.com/article/...-results-earnings-call-transcript

www.marketscreener.com/CRYOLIFE-INC-12185/...apshot-29486587/

www.marketscreener.com/CRYOLIFE-INC-12185/...esults-29485722/

seekingalpha.com/article/...ium=social&utm_source=twitter

www.marketscreener.com/CRYOLIFE-INC-12185/...apshot-29995691/

CryoLife: 4Q Earnings Snapshot

02/13/2020 | 05:12pm EST
KENNESAW, Ga. (AP) _ CryoLife Inc. (CRY) on Thursday reported a fourth-quarter loss of $681,000, after reporting a profit in the same period a year earlier.
On a per-share basis, the Kennesaw, Georgia-based company said it had a loss of 2 cents. Earnings, adjusted for amortization costs and non-recurring costs, were 10 cents per share.
The biological medical device maker posted revenue of $69.7 million in the period.
For the year, the company reported net income of $1.7 million, or 5 cents per share, swinging to a profit in the period. Revenue was reported as $276.2 million.
CryoLife expects full-year earnings in the range of 15 cents to 17 cents per share, with revenue in the range of $292 million to $298 million.
CryoLife shares have risen 11% since the beginning of the year. In the final minutes of trading on Thursday, shares hit $30.20, declining slightly in the last 12 months.
This story was generated by Automated Insights (automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CRY at www.zacks.com/ap/CRY
Automated Insights, source Associated Press News

seekingalpha.com/pr/...k-for-on-x-ascending-aortic-prosthesis

CryoLife Receives CE Mark for On-X® Ascending Aortic Prosthesis
Thu February 27, 2020 4:05 PM|PR Newswire|About: CRY
ATLANTA, Feb. 27, 2020 /PRNewswire/ -- CryoLife, Inc. (CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today it has received CE Mark for the On-X Ascending Aortic Prosthesis (AAP), allowing resumed distribution in the European Union.  The On-X AAP is indicated for the treatment of diseased, damaged or malfunctioning native or prosthetic heart valves in the aortic position involving an ascending aortic aneurysm.  These associated aortic root diseases coexist in as many as 10 percent of all aortic valve replacements.